Anti-hyperlipidemic effects of 500 mg spilanthol (SA3X) supplementation in people with dyslipidemia - a randomized, parallel-group placebo-controlled trial.

Q2 Medicine
Journal of Complementary and Integrative Medicine Pub Date : 2024-08-08 eCollection Date: 2024-09-01 DOI:10.1515/jcim-2024-0235
Kumar Guru Mishra, Nabnita Patnaik, Nihar Ranjan Pradhan
{"title":"Anti-hyperlipidemic effects of 500 mg spilanthol (SA3X) supplementation in people with dyslipidemia - a randomized, parallel-group placebo-controlled trial.","authors":"Kumar Guru Mishra, Nabnita Patnaik, Nihar Ranjan Pradhan","doi":"10.1515/jcim-2024-0235","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Dyslipidemia is a critical risk factor for cardiovascular disease. This study investigated the impact of 500 mg of spilanthol (SA3X) supplementation on lipid profiles in men with dyslipidemia using a randomized, parallel-group, placebo-controlled design.</p><p><strong>Methods: </strong>A total of 279 male participants were randomly allocated to one of four groups: SA3X without exercise, placebo without exercise, SA3X with exercise, and placebo with exercise. After a one-month control period, participants received SA3X capsules or placebo for three months. The exercise groups undertook standardized weight-lifting exercises four times weekly. Lipid profiles, biochemical parameters, and anthropometric measurements were monitored throughout and after the intervention.</p><p><strong>Results: </strong>Both SA3X groups exhibited significant reductions in total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) compared to the placebo groups. By day 90, the SA3X-no-exercise group showed a 16.78 % decrease in TC, while the SA3X-plus-exercise group demonstrated a 52.87 % decrease compared to placebo. Significant reductions in TG and LDL-C were noted at days 60 and 90 (p=0.01 and p=0.03, respectively). The SA3X-plus-exercise group also exhibited decreased random blood sugar levels at days 60 and 90 compared to placebo-plus-exercise. Moreover, decreases in C-reactive protein, creatine kinase, and serum creatinine levels were observed.</p><p><strong>Conclusions: </strong>SA3X supplementation, particularly when combined with exercise, effectively improved lipid profiles and various health markers in men with dyslipidemia. Adverse events, primarily taste disturbance, were mild. These findings suggest SA3X may be a promising adjunctive therapy for managing dyslipidemia, emphasizing its potential cardiovascular health benefits and supporting further investigation.</p><p><strong>Trial registration: </strong>CTRI/2021/05/033694; May 2021.</p>","PeriodicalId":15556,"journal":{"name":"Journal of Complementary and Integrative Medicine","volume":" ","pages":"384-395"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Complementary and Integrative Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/jcim-2024-0235","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Dyslipidemia is a critical risk factor for cardiovascular disease. This study investigated the impact of 500 mg of spilanthol (SA3X) supplementation on lipid profiles in men with dyslipidemia using a randomized, parallel-group, placebo-controlled design.

Methods: A total of 279 male participants were randomly allocated to one of four groups: SA3X without exercise, placebo without exercise, SA3X with exercise, and placebo with exercise. After a one-month control period, participants received SA3X capsules or placebo for three months. The exercise groups undertook standardized weight-lifting exercises four times weekly. Lipid profiles, biochemical parameters, and anthropometric measurements were monitored throughout and after the intervention.

Results: Both SA3X groups exhibited significant reductions in total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) compared to the placebo groups. By day 90, the SA3X-no-exercise group showed a 16.78 % decrease in TC, while the SA3X-plus-exercise group demonstrated a 52.87 % decrease compared to placebo. Significant reductions in TG and LDL-C were noted at days 60 and 90 (p=0.01 and p=0.03, respectively). The SA3X-plus-exercise group also exhibited decreased random blood sugar levels at days 60 and 90 compared to placebo-plus-exercise. Moreover, decreases in C-reactive protein, creatine kinase, and serum creatinine levels were observed.

Conclusions: SA3X supplementation, particularly when combined with exercise, effectively improved lipid profiles and various health markers in men with dyslipidemia. Adverse events, primarily taste disturbance, were mild. These findings suggest SA3X may be a promising adjunctive therapy for managing dyslipidemia, emphasizing its potential cardiovascular health benefits and supporting further investigation.

Trial registration: CTRI/2021/05/033694; May 2021.

在血脂异常人群中补充 500 毫克斯皮兰醇(SA3X)的抗高血脂作用--随机、平行组安慰剂对照试验。
目的:血脂异常是心血管疾病的一个重要危险因素。本研究采用随机、平行组、安慰剂对照设计,调查了补充 500 毫克斯皮兰醇(SA3X)对血脂异常男性血脂状况的影响:共有 279 名男性参与者被随机分配到四组中的一组:方法:279 名男性参与者被随机分配到四组中的一组:不运动的 SA3X 组、不运动的安慰剂组、运动的 SA3X 组和运动的安慰剂组。经过一个月的对照期后,参与者在三个月内服用 SA3X 胶囊或安慰剂。运动组每周进行四次标准化举重运动。在整个干预过程中和干预结束后,对血脂概况、生化参数和人体测量数据进行了监测:与安慰剂组相比,SA3X 两组的总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)均有明显下降。到第 90 天,与安慰剂组相比,SA3X 无运动组的总胆固醇下降了 16.78%,而 SA3X 加运动组则下降了 52.87%。在第 60 天和第 90 天,总胆固醇和低密度脂蛋白胆固醇显著降低(分别为 p=0.01 和 p=0.03)。与安慰剂加运动组相比,SA3X 加运动组在第 60 天和第 90 天的随机血糖水平也有所下降。此外,还观察到 C 反应蛋白、肌酸激酶和血清肌酐水平下降:结论:补充 SA3X,尤其是与运动相结合,能有效改善血脂异常男性的血脂状况和各种健康指标。不良反应(主要是味觉障碍)轻微。这些研究结果表明,SA3X可能是控制血脂异常的一种很有前景的辅助疗法,强调了它对心血管健康的潜在益处,并支持进一步的研究:试验注册:CTRI/2021/05/033694;2021 年 5 月。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Complementary and Integrative Medicine
Journal of Complementary and Integrative Medicine Medicine-Complementary and Alternative Medicine
CiteScore
3.10
自引率
0.00%
发文量
51
期刊介绍: Journal of Complementary and Integrative Medicine (JCIM) focuses on evidence concerning the efficacy and safety of complementary medical (CM) whole systems, practices, interventions and natural health products, including herbal and traditional medicines. The journal is edited by Ed Lui of the University of Western Ontario. Topics: -Quality, efficacy, and safety of natural health products, dietary supplements, traditional medicines and their synthetic duplicates -Efficacy and safety of complementary therapies -Evidence-based medicine and practice, including evidence of traditional use -Curriculum development, educational system and competency of complementary health programs -Methodologies on research and evaluation of traditional medicines and herbal products -Integrative medicine: basic and clinical research and practice -Innovation in CAM Curriculum -Educational Material Design
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信